Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Proximal tibial resorption in a modern total knee prosthesis.

Deen JT, Clay TB, Iams DA, Horodyski M, Parvataneni HK.

Arthroplast Today. 2017 Dec 6;4(2):244-248. doi: 10.1016/j.artd.2017.10.005. eCollection 2018 Jun.

2.

Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection.

Clay TD, Bowyer SE.

Anticancer Drugs. 2018 May 25. doi: 10.1097/CAD.0000000000000655. [Epub ahead of print]

PMID:
29846245
3.

Inferior vena cava filters (IVCFs): a review of uses and application to international guidelines at a single Australian center; implications of venous thromboembolism associated with malignancy.

Craven P, Daly C, Oates R, Sikotra N, Clay T, Gabbay E.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018776505. doi: 10.1177/2045894018776505. Epub 2018 Apr 25.

4.

Current Status of Gene Engineering Cell Therapeutics.

Saudemont A, Jespers L, Clay T.

Front Immunol. 2018 Feb 5;9:153. doi: 10.3389/fimmu.2018.00153. eCollection 2018. Review.

5.

A Revised Estimate of Costs Associated With Routine Preoperative Testing in Medicare Cataract Patients With a Procedure-Specific Indicator.

Chen CL, Clay TH, McLeod S, Chang HP, Gelb AW, Dudley RA.

JAMA Ophthalmol. 2018 Mar 1;136(3):231-238. doi: 10.1001/jamaophthalmol.2017.6372.

PMID:
29346472
6.

NEC-zero recommendations from scoping review of evidence to prevent and foster timely recognition of necrotizing enterocolitis.

Gephart SM, Hanson C, Wetzel CM, Fleiner M, Umberger E, Martin L, Rao S, Agrawal A, Marin T, Kirmani K, Quinn M, Quinn J, Dudding KM, Clay T, Sauberan J, Eskenazi Y, Porter C, Msowoya AL, Wyles C, Avenado-Ruiz M, Vo S, Reber KM, Duchon J.

Matern Health Neonatol Perinatol. 2017 Dec 18;3:23. doi: 10.1186/s40748-017-0062-0. eCollection 2017. Review.

7.

Microscopy of Common Nail Cosmetics.

Zimmer KA, Clay T, Vidal CI, Chaudhry S, Hurley MY.

Am J Dermatopathol. 2017 Nov;39(11):819-823. doi: 10.1097/DAD.0000000000000809.

PMID:
29058692
8.

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Solomon B, Dobrovic A, McLachlan SA, Moore MM.

Med Oncol. 2017 Sep 6;34(10):175. doi: 10.1007/s12032-017-1031-1.

PMID:
28879441
9.

Reproductive outcomes after non-occupational exposure to hexavalent chromium, Willits California, 1983-2014.

Remy LL, Byers V, Clay T.

Environ Health. 2017 Mar 6;16(1):18. doi: 10.1186/s12940-017-0222-8.

10.

Population level differences in thermal sensitivity of energy assimilation in terrestrial salamanders.

Clay TA, Gifford ME.

J Therm Biol. 2017 Feb;64:1-6. doi: 10.1016/j.jtherbio.2016.12.006. Epub 2016 Dec 16.

PMID:
28166938
11.

Proximate drivers of spatial segregation in non-breeding albatrosses.

Clay TA, Manica A, Ryan PG, Silk JR, Croxall JP, Ireland L, Phillips RA.

Sci Rep. 2016 Jul 21;6:29932. doi: 10.1038/srep29932.

12.

Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations.

Clay TD, Russell PA, Do H, Sundararajan V, Conron M, Wright GM, Dobrovic A, Moore MM, McLachlan SA.

Pathology. 2016 Jan;48(1):17-24. doi: 10.1016/j.pathol.2015.11.002. Epub 2015 Dec 12.

PMID:
27020204
13.

Revisit rates and associated costs after an emergency department encounter: a multistate analysis.

Duseja R, Bardach NS, Lin GA, Yazdany J, Dean ML, Clay TH, Boscardin WJ, Dudley RA.

Ann Intern Med. 2015 Jun 2;162(11):750-6. doi: 10.7326/M14-1616.

PMID:
26030633
14.

Preoperative medical testing in Medicare patients undergoing cataract surgery.

Chen CL, Lin GA, Bardach NS, Clay TH, Boscardin WJ, Gelb AW, Maze M, Gropper MA, Dudley RA.

N Engl J Med. 2015 Apr 16;372(16):1530-8. doi: 10.1056/NEJMsa1410846.

15.

A finding with a diagnosis: I just can't put my finger on it.

Lambe G, Le P, Clay TD.

BMJ Case Rep. 2014 Dec 22;2014. pii: bcr2014208665. doi: 10.1136/bcr-2014-208665.

16.

Outcomes of augmented allograft figure-of-eight sternoclavicular joint reconstruction.

Sabatini JB, Shung JR, Clay TB, Oladeji LO, Minnich DJ, Ponce BA.

J Shoulder Elbow Surg. 2015 Jun;24(6):902-7. doi: 10.1016/j.jse.2014.10.001. Epub 2014 Dec 3.

PMID:
25487906
18.

Telementoring: use of augmented reality in orthopaedic education: AAOS exhibit selection.

Ponce BA, Jennings JK, Clay TB, May MB, Huisingh C, Sheppard ED.

J Bone Joint Surg Am. 2014 May 21;96(10):e84. doi: 10.2106/JBJS.M.00928.

PMID:
24875036
19.

Individual (co)variation in standard metabolic rate, feeding rate, and exploratory behavior in wild-caught semiaquatic salamanders.

Gifford ME, Clay TA, Careau V.

Physiol Biochem Zool. 2014 May-Jun;87(3):384-96. doi: 10.1086/675974. Epub 2014 Apr 9.

PMID:
24769703
20.

The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma.

Clay TD, Do H, Sundararajan V, Moore MM, Conron M, Wright GM, McLachlan SA, Dobrovic A, Russell PA.

J Thorac Oncol. 2014 May;9(5):654-63. doi: 10.1097/JTO.0000000000000150.

21.

EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma.

Russell PA, Yu Y, Do H, Clay TD, Moore MM, Wright GM, Conron M, Wainer Z, Dobrovic A, McLachlan SA.

Pathology. 2014 Jan;46(1):32-6. doi: 10.1097/PAT.0000000000000027.

PMID:
24300726
22.

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK.

Ann Surg. 2013 Dec;258(6):879-86. doi: 10.1097/SLA.0b013e318292919e.

23.

Intravenous leiomyomatosis with intracardiac extension - a review of diagnosis and management with an illustrative case.

Clay TD, Dimitriou J, McNally OM, Russell PA, Newcomb AE, Wilson AM.

Surg Oncol. 2013 Sep;22(3):e44-52. doi: 10.1016/j.suronc.2013.03.004. Epub 2013 Apr 30. Review.

PMID:
23642379
24.

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.

Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP Jr, Jones FR, Lyerly HK.

Cancer Immunol Immunother. 2013 Aug;62(8):1293-301. doi: 10.1007/s00262-013-1400-3. Epub 2013 Apr 30.

25.

The effects of temperature and activity on intraspecific scaling of metabolic rates in a lungless salamander.

Gifford ME, Clay TA, Peterman WE.

J Exp Zool A Ecol Genet Physiol. 2013 Apr;319(4):230-6. doi: 10.1002/jez.1787. Epub 2013 Mar 12.

PMID:
23495133
26.

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy.

Brichard VG, Louahed J, Clay TM.

J Immunother. 2013 Feb;36(2):79-81. doi: 10.1097/CJI.0b013e3182829747. No abstract available.

PMID:
23377666
27.

Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.

D'Amato NC, Ostrander JH, Bowie ML, Sistrunk C, Borowsky A, Cardiff RD, Bell K, Young LJ, Simin K, Bachelder RE, Delrow J, Dawson A, Yee LD, Mrózek K, Clay TM, Osada T, Seewaldt VL.

PLoS One. 2012;7(9):e45684. doi: 10.1371/journal.pone.0045684. Epub 2012 Sep 25.

28.

Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

Ren XR, Wei J, Lei G, Wang J, Lu J, Xia W, Spector N, Barak LS, Clay TM, Osada T, Hamilton E, Blackwell K, Hobeika AC, Morse MA, Lyerly HK, Chen W.

Breast Cancer Res. 2012 Jun 7;14(3):R89.

29.

Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.

Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, Yang XY, Hobeika A, Burnett B, Devi GR, Clay TM, Smith J, Kim Lyerly H.

Cancer Immunol Immunother. 2012 Nov;61(11):1941-51. doi: 10.1007/s00262-012-1248-y. Epub 2012 Apr 10.

30.

Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.

Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS.

Mol Cancer Ther. 2012 Jul;11(7):1500-1509. doi: 10.1158/1535-7163.MCT-11-0937. Epub 2012 Feb 16.

31.

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA.

J Transl Med. 2012 Feb 10;10:28. doi: 10.1186/1479-5876-10-28. Erratum in: J Transl Med. 2013;11:82. Morse, Michael A [added].

32.

Pinch-off syndrome: a simple test is the best.

Clay TD.

Intern Emerg Med. 2012 Sep;7 Suppl 2:S141-3. doi: 10.1007/s11739-012-0760-6. Epub 2012 Feb 5. No abstract available.

PMID:
22311515
33.

Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.

Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, Kemper AR, Clay TM, Koeberl DD.

Hum Gene Ther. 2012 May;23(5):460-72. doi: 10.1089/hum.2011.063. Epub 2012 Mar 29.

34.

Acute pain associated with oxaliplatin infusion: case report and literature review.

Clay TD, Ashley DA.

J Oncol Pharm Pract. 2012 Dec;18(4):421-4. doi: 10.1177/1078155211428999. Epub 2011 Nov 11.

PMID:
22080592
35.

Increasing vaccine potency through exosome antigen targeting.

Hartman ZC, Wei J, Glass OK, Guo H, Lei G, Yang XY, Osada T, Hobeika A, Delcayre A, Le Pecq JB, Morse MA, Clay TM, Lyerly HK.

Vaccine. 2011 Nov 21;29(50):9361-7. doi: 10.1016/j.vaccine.2011.09.133. Epub 2011 Oct 12.

36.

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

Morse MA, Hobeika A, Serra D, Aird K, McKinney M, Aldrich A, Clay T, Mourich D, Lyerly HK, Iversen PL, Devi GR.

Cancer Gene Ther. 2012 Jan;19(1):30-7. doi: 10.1038/cgt.2011.63. Epub 2011 Oct 14.

PMID:
21997230
37.

Minimizing complications in autoimmune blistering diseases.

Clay T, Pandya AG.

Dermatol Clin. 2011 Oct;29(4):577-83. doi: 10.1016/j.det.2011.06.005. Review.

PMID:
21925001
38.

New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.

Hamilton E, Clay TM, Blackwell KL.

Cancer Invest. 2011 Oct;29(8):533-41. doi: 10.3109/07357907.2011.605413. Epub 2011 Aug 15. Review.

PMID:
21843051
39.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group.

J Transl Med. 2011 Jul 11;9:108. doi: 10.1186/1479-5876-9-108.

40.

Immunologic monitoring of cellular immune responses in cancer vaccine therapy.

Whiteside TL, Gulley JL, Clay TM, Tsang KY.

J Biomed Biotechnol. 2011;2011:370374. doi: 10.1155/2011/370374. Epub 2011 Jun 7. No abstract available.

41.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

42.

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.

Morse MA, Chapman R, Powderly J, Blackwell K, Keler T, Green J, Riggs R, He LZ, Ramakrishna V, Vitale L, Zhao B, Butler SA, Hobeika A, Osada T, Davis T, Clay T, Lyerly HK.

Clin Cancer Res. 2011 Jul 15;17(14):4844-53. doi: 10.1158/1078-0432.CCR-11-0891. Epub 2011 Jun 1.

43.

The impact of statistical choices on neonatal intensive care unit quality ratings based on nosocomial infection rates.

Lee HC, Chien AT, Bardach NS, Clay T, Gould JB, Dudley RA.

Arch Pediatr Adolesc Med. 2011 May;165(5):429-34. doi: 10.1001/archpediatrics.2011.41.

44.

Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.

Osada T, Chen M, Yang XY, Spasojevic I, Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA, Lyerly HK.

Cancer Res. 2011 Jun 15;71(12):4172-82. doi: 10.1158/0008-5472.CAN-10-3978. Epub 2011 Apr 29.

45.

HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.

Hartman ZC, Yang XY, Glass O, Lei G, Osada T, Dave SS, Morse MA, Clay TM, Lyerly HK.

Cancer Res. 2011 Jul 1;71(13):4380-91. doi: 10.1158/0008-5472.CAN-11-0308. Epub 2011 Apr 25.

46.

MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.

Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, Hafner J, Philip M, Clay TM, Lyerly HK, Philip R.

Clin Cancer Res. 2011 May 15;17(10):3408-19. doi: 10.1158/1078-0432.CCR-10-2614. Epub 2011 Feb 7.

47.

Depletion of human regulatory T cells.

Hobeika AC, Morse MA, Osada T, Peplinski S, Lyerly HK, Clay TM.

Methods Mol Biol. 2011;707:219-31. doi: 10.1007/978-1-61737-979-6_14.

PMID:
21287338
48.

Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Lyerly HK.

Immunol Res. 2011 Apr;49(1-3):235-47. doi: 10.1007/s12026-010-8186-6.

49.

CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S.

J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512. doi: 10.1093/jnci/djq343. Epub 2010 Sep 17.

50.

Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.

Hartman ZC, Osada T, Glass O, Yang XY, Lei GJ, Lyerly HK, Clay TM.

Cancer Res. 2010 Sep 15;70(18):7209-20. doi: 10.1158/0008-5472.CAN-10-0905. Epub 2010 Sep 7.

Supplemental Content

Support Center